MichBio was privileged to moderate a Congressional briefing on H.R. 6000, the Cures 2.0 legislation. Several other state groups including BioNJ, Health Institute of New Jersey, California Life Sciences, Life Sciences PA, and Biocom California partnered to co-host the event. The over 125 attendees heard directly from the featured guests and bill’s sponsors, Michigan’s Rep. Fred Upton and Colorado’s Rep. Diana DeGette.
Cures 2.0 is the follow-up legislation to the landmark, bipartisan 21st Century Cures Act of 2016, that led to the streamlining and improvements in medical care, research, drug development and more. Max Schill, a 13-year old patient who advocated for the original legislation in 2016 at age 5 participated too and provided his perspectives for the need to enact the bill.
Reps. DeGette and Upton described how Cures 2.0 seeks to make new treatments more accessible to patients by taking advantage of new technologies and modernization efforts to improve approval and regulatory processes, bring more patient empowerment and engagement in drug development and clinical trials, build on infrastructure goals to expand telehealth and improve public health and preparedness, and develop coverage and payment models for innovative treatments.
The webinar can be viewed here.